PRDI-BF1 and PRDI-BF1β isoform expressions correlate with disease status in multiple myeloma patients

• Published in: Hematology reports Vol. 9; no. 4; p. 7201
• Main Authors: Buda, Gabriele, Guerrini, Francesca, Galimberti, Sara, Orciuolo, Enrico, Pacini, Simone, Mazzantini, Elisa, Petrini, Mario
• Format: Journal Article
• Language: English
• Published: Pavia MDPI AG 22.12.2017; PAGEPress Scientific Publications, Pavia, Italy
• Subjects: Bone marrow; Hematology, Multiple Myeloma, multi drug resistance; Multiple myeloma; Patients; Plasma cells; Polymerase chain reaction; Tumor cell lines
• ISSN: 2038-8322; 2038-8330
• DOI: 10.4081/hr.2017.7201

Human positive regulatory domain I binding factor 1 (PRDI-BF1 or BLIMP-1) is a transcription factor that acts as a master regulator and has crucial roles in the control of differentiation and in maintaining survival of plasma cells (PC). The PRDM1 gene, which codifies for PRDI-BF1, contains an alternative promoter capable of generating a PRDI-BF1 deleted protein (called PRDI-BF1β), which lacks 101 amino acids comprising most of the regulatory domain. PRDI-BF1β has been detected in relevant quantities especially in multiple myeloma cell lines (U266 and NCI- H929). The first aim of the study was to compare, using real time polymerase chain reaction (RT-PCR), the levels of PRDI-BF1 and PRDI-BF1β in myeloma patients and in normal human bone marrow. The second step was the examination of the expression of PRDI-BF1 and PRDI-BF1β isoform depending on disease status and treatment response. We demonstrate the correlation of PRDI-BF1 and the shorter PRDI-BF1β isoform protein levels with the clinical evolution and the management of myeloma patients.